fingolimod hydrochloride has been researched along with Leucocythaemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chew, YC; Chow, D; Edinger, AL; Edson, JA; Keebaugh, A; Kemp, JA; Kleinman, MT; Kwon, YJ; McCracken, AN | 1 |
| Abdel-Wahab, O; Apperley, J; Arlinghaus, RB; Bittman, R; Briesewitz, R; Caligiuri, MA; Eisfeld, AK; Ferenchak, G; Goldman, JM; Harb, JG; Levine, R; Marcucci, G; Milojkovic, D; Nagata, K; Neviani, P; Oaks, JJ; Ogretmen, B; Perrotti, D; Quintas-Cardama, A; Reid, A; Roof, S; Saddoughi, SA; Santhanam, R; Van Brocklyn, JR; Walker, CJ; Ziolo, MT | 1 |
| Byrd, JC; Chen, CS; Kwak, KJ; Lee, LJ; Lee, RJ; Mao, Y; Muthusamy, N; Phelps, MA; Wang, J; Wu, Y; Zhao, Y | 1 |
| Barr, SA; Brandt, C; Chen, B; Clare, S; Edinger, AL; Fallegger, D; Fransson, R; Hanessian, S; Huwiler, A; Keebaugh, A; Kim, SM; Kleinman, MT; Liu, G; McCracken, AN; McMonigle, RJ; Moitessier, N; Müschen, M; Perryman, MS; Roy, SG; Selwan, E; Sernissi, L; Snider, AJ; Tessier, J | 1 |
| Aliaga, C; Amin, S; Baab, KT; Broeg, K; Desai, D; Dewey, A; Fox, T; Hirsch, L; Jarbadan, NR; Kester, M; Li, Y; Liao, A; Liao, J; Liu, X; Loughran, K; Loughran, TP; Rogers, A; Ryland, L; Shah, MV; Tan, SF; Wang, HG; Watters, R; Yang, J; Zhang, LQ | 1 |
| Ikekita, M; Matsuoka, Y; Nagahara, Y; Shinomiya, T | 1 |
6 other study(ies) available for fingolimod hydrochloride and Leucocythaemia
| Article | Year |
|---|---|
Biocompatible Chemotherapy for Leukemia by Acid-Cleavable, PEGylated FTY720.
Topics: Acetals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Fingolimod Hydrochloride; Humans; Hydrogen-Ion Concentration; Leukemia; Phosphorylation; Polyethylene Glycols | 2020 |
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.
Topics: Animals; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Class Ib Phosphatidylinositol 3-Kinase; DNA-Binding Proteins; Enzyme Activation; Fingolimod Hydrochloride; Histone Chaperones; Humans; Immunoblotting; Immunosuppressive Agents; Janus Kinase 2; Kaplan-Meier Estimate; Leukemia; Mice; Mice, SCID; Mutation; Oncogene Proteins; Propylene Glycols; Protein Kinase C; Protein Phosphatase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sphingosine; Treatment Outcome | 2013 |
A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.
Topics: Animals; Antigens, CD19; Antigens, CD20; Antigens, Neoplasm; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Leukemia; Liposomes; Mice; Mice, Inbred ICR; Nanomedicine; Propylene Glycols; Sphingosine; Tetraspanins; Water | 2014 |
Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fingolimod Hydrochloride; Humans; Leukemia; Mice; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Receptors, Lysosphingolipid; Xenograft Model Antitumor Assays | 2017 |
Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.
Topics: Animals; Apoptosis; Blotting, Western; Cell Proliferation; Chronic Disease; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Killer Cells, Natural; Leukemia; Male; Myeloid Cell Leukemia Sequence 1 Protein; Propylene Glycols; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344; RNA, Small Interfering; Sphingosine | 2011 |
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells.
Topics: Blood Cells; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; In Vitro Techniques; Leukemia; Phosphorylation; Propylene Glycols; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Sphingosine; U937 Cells | 2003 |